Vivacta Bio Secures Over $50 Million in Series A Funding to Advance In Vivo CAR-T Therapy GT801
核心洞察
Vivacta Biotechnology (搜索) completed Series A and Series A+ financing rounds totaling over $50 million, led by Loyal Valley Capital (搜索) and Decheng Capital (搜索) with participation from OrbiMed (搜索) and other renowned investors.
The company's flagship product GT801 (搜索), an in vivo CAR-T (搜索) therapy, has demonstrated promising safety and efficacy profiles in early clinical studies for hematological malignancies (搜索) and autoimmune diseases (搜索).
Funding will support GT801 (搜索) clinical trials advancement, regulatory submissions, research team expansion, and global operations in the in vivo CAR-T (搜索) field.
Vivacta Biotechnology (搜索) (Shanghai) Co., Ltd., a biotechnology company pioneering in vivo CAR-T (搜索) cell therapies, announced the completion of Series A and Series A+ financing rounds totaling over $50 million. The funding represents a significant milestone for the company's innovative approach to CAR-T therapy development and positions it for accelerated clinical advancement.
Funding Details and Investor Support
The two financing rounds were led by Loyal Valley Capital (搜索) and Decheng Capital (搜索) respectively, with participation from a consortium of global investors including OrbiMed (搜索), Hankang Capital, Eisai Innovation Inc., and C&D Emerging Industry Equity Investment. Existing shareholders Qiming Venture Partners, Beijing Shunxi, and Apricot Capital also participated in the rounds.
The diverse investor base comprises both global industrial capital and specialist biotechnology investors, highlighting the broad recognition of Vivacta's innovative technology platform. Following the Series A+ closing, Mr. Xie Ronggang from Loyal Valley Capital (搜索) and a partner from DC Global Ventures joined Vivacta's board of directors.
GT801 Clinical Progress and Therapeutic Potential
Vivacta's core asset, GT801 (搜索), represents a next-generation in vivo CAR-T (搜索) therapy that has shown significant potential in early clinical studies. According to Dr. Liu Yarong, Founder and CEO of Vivacta, "GT801 has demonstrated promising safety and efficacy profiles in early clinical studies across hematological malignancies (搜索) and autoimmune disease patients, potentially offering these patient populations a transformative treatment option."
The company recently presented initial human data for GT801 (搜索) via an oral report at the American Society of Hematology Annual Meeting & Exposition 2025 (ASH 2025) in December 2025, marking an important clinical milestone for the program.
Strategic Use of Funding
The proceeds from the financing rounds will support multiple strategic initiatives critical to Vivacta's development trajectory. The funding will advance clinical trials for GT801 (搜索), support regulatory submission and approval processes, and enable expansion of the research team and platform capabilities. Additionally, the capital will accelerate Vivacta's global expansion efforts in the in vivo CAR-T (搜索) field.
Company Vision and Market Position
Vivacta is dedicated to pioneering in vivo CAR-T (搜索) cell therapy with a commitment to delivering transformative treatments for both cancer patients and those with autoimmune diseases (搜索). The company's approach represents a novel advancement in the CAR-T therapy landscape, potentially offering broader patient access compared to traditional ex vivo CAR-T approaches.
Dr. Liu Yarong emphasized the company's mission, stating, "Vivacta is committed to advancing innovative in vivo CAR-T (搜索) cell therapies... to deliver innovative therapies to more patients in need." This vision aligns with the growing need for more accessible and scalable CAR-T therapeutic options in the oncology and autoimmune disease treatment landscape.